MedTrace Logo

PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies

NCT03030001 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-01-24

No results posted yet for this study

Summary

This is a single-arm, open-label, one center, dose escalation clinical study, to determine the safety and efficacy of infusion of autologous T cells engineered to express immune checkpoint antibody and chimeric antigen receptor targeting mesothelin in adult patients with mesothelin positive, recurrent or refractory malignant tumors.

Conditions

Interventions

BIOLOGICAL

PD-1 antibody expressing mesothelin specific CAR-T cells

Patients will receive an IV infusion of PD-1 antibody expressing mesothelin specific CAR engineered peripheral blood leukocyte. On day 21, cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes.

Sponsors & Collaborators

  • Ningbo Cancer Hospital

    lead INDUSTRY

Principal Investigators

  • Qijun Qian, PhD · Shanghai Cell Therapy Engineering Research Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-15
Primary Completion
2018-12-01
Completion
2019-02-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03030001 on ClinicalTrials.gov